Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
11/2003
11/27/2003WO2002078730A3 Use of neublastin polypeptides for treating neuropathic pain
11/27/2003WO2002078604A3 Transdermal delivery of bioactive material
11/27/2003WO2002072632A3 Nucleic acids of the human abcc11 gene, vectors containing such nucleic acids and uses thereof.
11/27/2003WO2002067903A3 Compositions and methods of manufacture for oral dissolvable dosage forms
11/27/2003WO2002061109A3 Yeast strains autonomously producing steroids
11/27/2003WO2002057242A3 Urea derivatives as integrin alpha 4 antagonists
11/27/2003WO2002049625A3 Compounds that affect cd83 expression, pharmaceutical compositions comprising said compounds and methods for identifying said compounds
11/27/2003WO2002046424A3 Fibroblast growth factors
11/27/2003US20030221206 Using in vitro fertilization to produce gentically engineered animals for use as models for prevention and treatment of disease
11/27/2003US20030221205 Olfactory and pheromones G-protein coupled receptors
11/27/2003US20030220489 29 human secreted proteins
11/27/2003US20030220484 Modified ciliary neurotrophic factors
11/27/2003US20030220483 Comprises fibroblast growth factor homologous factor- 1 (FHF-1) for disgnosing, prevention and treatment of neurodegenerative or neoplastic disorders
11/27/2003US20030220480 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
11/27/2003US20030220478 Novel compounds
11/27/2003US20030220468 Modified forms of pharmacologically active agents and uses therefor
11/27/2003US20030220397 Cyclic amino acids and derivatives thereof useful as pharmaceutical agents
11/27/2003US20030220393 Substituted phthalides, a process for their preparations and pharmaceutical compositions containing them
11/27/2003US20030220390 Carbocyclic oxy amines such as 2-benzylidene-6-dimethylamino methylcyclohexanone, used as analgesics
11/27/2003US20030220389 Tertiary amines such as 2-dimethylaminomethyl-1-(3-methoxy-phenyl)-6-methylcyclohexanol, used as analgesics
11/27/2003US20030220382 Amines such as 2-((2-N,N-di-n-pentylamino)-indan-5-yl)amino-5 -nitro-benzoic acid, administered for prophylaxis of Alzheimer's disease
11/27/2003US20030220375 N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives
11/27/2003US20030220372 Imidazole compounds as anti-inflammatory and analgesic agents
11/27/2003US20030220368 Superior Na+ channel inhibition activity; antiarrhythmic agents
11/27/2003US20030220367 Administering a therapeutical carbamate derivative to a patient as prostaglandin IP (12 or PGI2) antagonists
11/27/2003US20030220362 Novel inhibitors of formation of advanced glycation endproducts (AGEs)
11/27/2003US20030220359 Substituted pyrimidine-sulfonamide derivatives are used as endothelin receptor antagonists
11/27/2003US20030220353 Useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3
11/27/2003US20030220349 Related to organ systems which respond to estrogen agonists or antagonists; in particular, 2-phenyl-3-aroylbenzothiophenes and 1-(alkylaminoethoxy phenyl)-1-phenyl-2-phenylbut-1-enes have wide application as estrogen agonists
11/27/2003US20030220342 Use of such compounds as corticotropin releasing factor receptor antagonists in the treatment of various neurological disorders
11/27/2003US20030220335 Benzoxazines for use in the treatment of parkinson's disease
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220325 Such as 1-(4-(phenylsulfonyl)-naphthyl)piperazine; for treating treating diseases related to 5-HT receptor; radiolabelling
11/27/2003US20030220322 Substituted 3,4-dihydro-pyrimido[1,2a]pyrimidines and 3,4-dihydro-pyrazino[1,2a]pyrimidines, and methods for their preparation and use
11/27/2003US20030220321 Such as 10-(2-ethoxyphenyl)-1,2,3,4,5,6-hexahydroazepino(4,5-b)indole; for treatment of anxiety, depression, schizophrenia, epilepsy, migraine, Alzheimers disease, sleep disorders, obesity, stress related diseases, and/or drug withdrawal
11/27/2003US20030220319 Such as 1-(4,5-dihydro-1H-imidazol-2-ylmethyl)-3-methanesulfonyl-2-methyl-1H-indole for preventing/treating disorders modulated by alpha-1A/L adrenoceptors such as urinary incontinence and sexual disorders
11/27/2003US20030220318 New phenylalanine derivatives
11/27/2003US20030220316 Such as N-(1-(1-methylethyl)piperidin-4-yl)-N-((4-methyl phenyl)methyl)-4-methoxyphenylacetamide for stimulation of serotonin receptors
11/27/2003US20030220309 17-methylenandrostan-3alpha-ol analogs as CRH inhibitors
11/27/2003US20030220306 Transcripts harboring inton 1, or fragment thereof; preventing or treating Alzheimer's Disease; ameliorating a neurodegenerative condition; modulating amyloid precursor protein; selectively inhibiting COX-3 or PCOX-1a activity
11/27/2003US20030220303 GABAB Receptor Agonists; used to treat gastrointestinal disorders, especially GERD
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220280 Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration
11/27/2003US20030220248 Use of MP52 or MP121 for the treatment and prevention of diseases of the nervous system
11/27/2003US20030220235 Muteins of the CGRP 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers
11/27/2003US20030220232 Peptide with the sequence Gln-Tyr-Asn-Ala-Asp and derivatives differing from the original sequence by the addition, substitution, inversion, insertin, deletion or modification of one or more amino acids; sodium ion channel binder
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030219898 Novel mammalian multipotent stem cells and compositions, methods of preparation and methods of administration thereof
11/27/2003US20030219875 Albumin fusion proteins
11/27/2003US20030219874 Comprises endothelial differentiation gene receptor proteins (EDG8) for monitoring receptivity to and/or diagnosing cancer, angiogenesis and inflammation
11/27/2003US20030219864 Novel variants of RANKL protein
11/27/2003US20030219494 Compositions and methods of using them
11/27/2003US20030219489 Solid pharmaceutical dispersions with enhanced bioavailability
11/27/2003US20030219476 Administering to a mammal a pharmaceutical formulation containing mitoxantrone in a cardiolipin (a liposome), and a excipient to treat cancer and multiple sclerosis
11/27/2003US20030219439 Genetic enginieered mixtures of complementary determining regions(CDR) antigens used for analyzing neutralizing epitopes and for prophylaxis of allergies and respiratory system disorders
11/27/2003US20030219438 Human antibodies that bind human TNFalpha
11/27/2003US20030219430 Methods of preventing or treating brain ischemia or brain injury
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219375 Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2497601A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
11/27/2003CA2493825A1 Means for use in treating diseases correlated with or caused by non-physiological levels of microtubule-associated pp2ac
11/27/2003CA2486576A1 Sodium channel regulators and modulators
11/27/2003CA2486468A1 Improvements in delivery technology
11/27/2003CA2486342A1 Compounds which can block the response to chemical substances or thermal stimuli or mediators of inflammation of nociceptors, production method thereof and compositions containingsame
11/27/2003CA2486339A1 Substituted ring-fused imidazole derivates: gabaa receptor ligands
11/27/2003CA2486302A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003CA2486157A1 Opioid and opioid-like compounds and uses thereof
11/27/2003CA2486147A1 Treatment of crohn's disease or psoriasis using anti-inteferon gamma antibodies
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486106A1 Compounds and methods for inhibiting selectin-mediated function
11/27/2003CA2486092A1 Aminotetralin-derived urea modulators of vanilloid vr1 receptor
11/27/2003CA2486000A1 Use of compounds that are effective as selective opiate receptor modulators
11/27/2003CA2485966A1 Novel substituted sulfamate anticonvulsant derivatives
11/27/2003CA2485466A1 Treatment of neuropathic pain
11/27/2003CA2485081A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2484646A1 Hormone replacement therapy using a combination of conjugated estrogens and trimegestone
11/27/2003CA2484631A1 Phenyl substituted imidazopyridines and phenyl substituted benzimidazoles
11/27/2003CA2484308A1 Substituted quinolone carboxylic acids, their derivatives, site of action, and uses thereof
11/27/2003CA2484233A1 Multicyclic compounds for use as melanin concentrating hormone antagonists in the treatment of obesity and diabetes
11/27/2003CA2483770A1 Trimegestone and estrogens for treating post menopausal disorders
11/27/2003CA2483619A1 Novel compounds and their use
11/27/2003CA2482756A1 Indole derivatives and the use thereof as cb<sb>2</sb> receptor ligands
11/27/2003CA2482746A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003CA2482348A1 Combinations of an ace inhibitor, a calcium channel blocker and a diuretic
11/26/2003EP1365246A1 Diagnostics and therapeutics for diseases associated with neuromedin U2 receptor (NMU2)
11/26/2003EP1365024A1 Traf3-binding b cell-specific receptor
11/26/2003EP1365018A1 CD100 semaphorin in myelination
11/26/2003EP1364952A1 Bicyclic nitrogenous fused-ring compound
11/26/2003EP1364949A1 Jnk inhibitor
11/26/2003EP1364943A1 Novel cystine derivatives and inhibitors for the activation of inflammatory factors
11/26/2003EP1364655A1 Method for enhancing functional recovery of motor coordination, speech or sensory perception after central nervous system ischemia or trauma
11/26/2003EP1364653A1 Casoase 3 inhibitors
1 ... 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 ... 1833